Nemaura Medical Inc.

Equities

NMRD

US6404422080

Medical Equipment, Supplies & Distribution

Delayed OTC Markets 10:06:50 2024-04-25 am EDT 5-day change 1st Jan Change
0.06 USD -7.69% Intraday chart for Nemaura Medical Inc. -24.81% -72.60%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nemaura Medical Inc. Announces Board Changes CI
Nemaura Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Nemaura Medical Inc.(OTCPK:NMRD) dropped from S&P TMI Index CI
Nemaura Medical Inc.(OTCPK:NMRD) dropped from NASDAQ Composite Index CI
Nemaura Medical Rolls Out Metabolic Health Program in UK MT
Nemaura Medical Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs CI
Nemaura Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Nemaura Medical Says Nasdaq Listing Standards Probably Won't Be Met by Deadline MT
Nemaura Medical Announces Interim Results from Its Metabolic Health Program CI
Nemaura Medical Says Interim Study Results Show Possibility of 24-Hour Glucose Meter Use MT
Nemaura Medical Completes 100 Patient Study for Sugarbeat® 24-Hour Wear and Reports Interim Results CI
HC Wainwright Adjusts Price Target on Nemaura Medical to $2.50 From $7, Maintains Buy Rating MT
Nemaura Medical Secures Approval for sugarBEAT Glucose Sensor in Saudi Arabia MT
Nemaura Medical Inc. Announces SFDA Approval of SugarBEAT® CI
Nemaura Medical Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Nemaura Medical Receives $6.5 Million in New Funding MT
EF Hutton Adjusts Price Target on Nemaura Medical to $4 From $6, Maintains Buy Rating MT
Nemaura Medical Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Nemaura Medical Inc. Auditor Raises 'Going Concern' Doubt CI
Nemaura Medical, Inc. Announces Next Commercialization Stage of Its proBEAT Sensor CI
North American Morning Briefing : Stock Futures -2- DJ
Nemaura Medical Inc.(NasdaqCM:NMRD) dropped from Russell Microcap Growth Index CI
Nemaura Medical Inc.(NasdaqCM:NMRD) dropped from Russell Microcap Index CI
Nemaura Medical Inc.(NasdaqCM:NMRD) dropped from Russell 3000E Index CI
Nemaura Medical Inc.(NasdaqCM:NMRD) dropped from Russell 3000E Growth Index CI
Chart Nemaura Medical Inc.
More charts
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.065 USD
Average target price
1.5 USD
Spread / Average Target
+2,207.69%
Consensus